A Barcelona stroke-device company
Barcelona, SpainMedtech
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Growth late-stage financing Verified against 3 sources | $56M | 2026-09-23 | Omega Funds | 3 outlets. #60 in Trending |
[ VERIFIED · CORRECTED ]1.00 read against 3 sources
[ BUILT WITH ]·[ SEARCH ]found by Firecrawl search: "seed round" funding announcement startup·[ SCRAPE ]3 pages read: techstartups.com, fiercebiotech.com, globenewswire.com·[ JSON ]round extracted with a schema, grounded to one sentence·[ VERIFY ]correctedread back across 3 sources·[ BRANDING ]homepage not matched·[ AGENT ]dossier built by the Firecrawl agent | ||||
| Round | Amount | Announced | Lead |
|---|---|---|---|
| Seed | n/a | undated | not stated |
| Series A | 15 million Euro | 2017-05-22 | Ysios Capital, Innogest Capital, Omega Funds |
Anaconda is tackling a large clinical problem: the company says strokes cause seven million deaths annually and that its funnel catheter is designed to improve clot capture, reduce embolic complications and maximize brain reperfusion. The $56 million financing is intended to complete the 327-subject ATHENA pivotal study and support product development and regulatory approvals, while the company already has CE mark approval for ANA5 but its U.S. funnel catheter remains investigational.
Checked against 12 sources today
No homepage passed the identity check, so nothing was written. Refresh profile tries again with what the record now knows.